A recent study reveals that patients who discontinue popular GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Findings released in a major medical journal points out that while obese people often shed substantial amounts of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users purchasing such medications should be cognizant of the potential of rapid rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to original mass in about a year and a half.
Comparing Therapies
The study, which looked at dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
The team note that people who shed pounds through diet and exercise typically have a more gradual creep back—around 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists believe the mechanism of the jabs accounts for the heightened regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than normal may cause the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means appetite is unsuppressed, making binge eating far more likely."
An Ongoing Disease?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, considering the likelihood of weight regain, the therapy is often life-long.
This perspective is supported by drug manufacturers, who note that the findings "highlight the long-term nature of excess weight," similar to managing conditions like hypertension.
User Accounts
Individuals who have stopped the jabs describe a powerful return of hunger.
"It was like a switch that goes on and I was suddenly ravenous," said a patient.
The struggle is exacerbated if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Survey data show that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Use is higher among females compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone solution and long-term success likely depends on ongoing lifestyle support.
